Clinical Report: Effectiveness of Ustekinumab in Managing Perianal Fistulizing Crohn's Disease
Overview
This multicenter retrospective analysis evaluated the effectiveness of Ustekinumab (UST) in patients with perianal fistulizing Crohn's disease (pfCD). The study enrolled 163 patients and assessed fistula response and clinical remission rates over a median follow-up of 15 months.
Background
Perianal fistulizing Crohn’s disease is a challenging complication of Crohn’s disease, affecting a significant proportion of patients and often leading to pain and reduced quality of life. Traditional treatments, particularly anti-TNF agents, may fail in a subset of patients, necessitating alternative therapies. Ustekinumab, a monoclonal antibody targeting interleukin-12 and interleukin-23, has been studied for its efficacy in this context.
Data Highlights
Outcome
Rate
Fistula Response
88.3%
Clinical Remission
70.1%
CRP Improvement
21.2 ± 28.3 → 5.2 ± 8.9 mg/L
ESR Improvement
36.6 ± 24.5 → 14.5 ± 18.3 mm/h
Hemoglobin Improvement
126.8 ± 18.5 → 148.2 ± 25.6 g/L
Adverse Event Rate
7.4%
Key Findings
Fistula response rate was 88.3% and clinical remission rate was 70.1% at final follow-up.
Significant improvements in inflammatory biomarkers were observed (CRP, ESR, hemoglobin).
Definitive surgery and fewer prior biologic treatments were identified as independent predictors of healing.
The developed nomogram showed good discriminative ability for predicting 24-week remission (AUC = 0.852).
UST was well-tolerated with an adverse event rate of 7.4% and no severe safety issues reported.
Clinical Implications
The study provides data on the effectiveness of Ustekinumab in managing perianal fistulizing Crohn's disease, particularly in patients with fewer prior biologic exposures.
Conclusion
Ustekinumab demonstrates efficacy in managing perianal fistulizing Crohn's disease, with reported response rates and a manageable safety profile.
